APA

von Minckwitz G., Puglisi F., Cortes J., Vrdoljak E., Marschner N., Zielinski C., Villanueva C., Romieu G., Lang I., Ciruelos E., De Laurentiis M., Veyret C., de Ducla S., Freudensprung U., Srock S. & Gligorov J. (20150127). Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. : The Lancet. Oncology.

Chicago

von Minckwitz Gunter, Puglisi Fabio, Cortes Javier, Vrdoljak Eduard, Marschner Norbert, Zielinski Christoph, Villanueva Cristian, Romieu Gilles, Lang István, Ciruelos Eva, De Laurentiis Michele, Veyret Corinne, de Ducla Sabine, Freudensprung Ulrich, Srock Stefanie and Gligorov Joseph. 20150127. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. : The Lancet. Oncology.

Harvard

von Minckwitz G., Puglisi F., Cortes J., Vrdoljak E., Marschner N., Zielinski C., Villanueva C., Romieu G., Lang I., Ciruelos E., De Laurentiis M., Veyret C., de Ducla S., Freudensprung U., Srock S. and Gligorov J. (20150127). Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. : The Lancet. Oncology.

MLA

von Minckwitz Gunter, Puglisi Fabio, Cortes Javier, Vrdoljak Eduard, Marschner Norbert, Zielinski Christoph, Villanueva Cristian, Romieu Gilles, Lang István, Ciruelos Eva, De Laurentiis Michele, Veyret Corinne, de Ducla Sabine, Freudensprung Ulrich, Srock Stefanie and Gligorov Joseph. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. : The Lancet. Oncology. 20150127.